DR. JEFFREY H. MARGOLIS M.D. NPI 1871577544

NPI Details

DR. Jeffrey H. Margolis, M.D. is a hematology and oncology internal medicine in Madison Heights, MI with 32 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Jeffrey H. Margolis, M.D. NPI is 1871577544. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: CLVLND CLINIC LERNER COLLEGE OF MED OF CASE WSTN RSV UNIVERSITY
Graduation Year:1993

The provider's business location address is:

27301 DEQUINDRE RD
SUITE314
MADISON HEIGHTS, MI
ZIP 48071-473
Phone: (248) 399-4400
Fax: (248) 399-4840

The NPI 1871577544 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, basic group of blood chemicals (calcium, ionized) (HCPCS:80047)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Unclassified drugs (HCPCS:J3490)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Injection of drug or substance into vein (HCPCS:96374)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Influenza vaccine split virus, preservative free (HCPCS:90662)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Urea nitrogen level to assess kidney function, quantitative (HCPCS:84520)
• Blood creatinine level (HCPCS:82565)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Bilirubin level, total (HCPCS:82247)
• Influenza vaccine, quadrivalent, 0.5 ml dosage (HCPCS:90688)

The enumeration date for this NPI number is 12/6/2005 and was last updated on 2/24/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.